BRAF inhibitors vs chemotherapy alone
Overall survival† · people with cutaneous melanoma
BRAF inhibitors leads to lower overall survival† compared with chemotherapy (high certainty).
1 finding from 1 review
- HR 0.4 [0.28, 0.57]925 participantsHigh
Findings
What do systematic reviews say?
8 questions · 8 findings · 1 reviews
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 12.5%Moderate 2 · 25%High 5 · 62.5%
BRAF inhibitors vs chemotherapy alone
Progression‐free survival · people with cutaneous melanoma
BRAF inhibitors leads to lower progression‐free survival† compared with chemotherapy (high certainty).
1 finding from 1 review
- HR 0.27 [0.21, 0.34]925 participantsHigh
BRAF inhibitors vs chemotherapy alone
Tumour response · people with cutaneous melanoma
BRAF inhibitors leads to higher tumour response compared with chemotherapy (high certainty).
1 finding from 1 review
- RR 6.78 [4.84, 9.49]925 participantsHigh
BRAF inhibitors vs chemotherapy alone
Toxicity (≥ G3) · people with cutaneous melanoma
BRAF inhibitors showed no clear difference in toxicity (≥ G3) compared with chemotherapy (low certainty).
1 finding from 1 review
- RR 1.27 [0.48, 3.33]408 participantsLow
BRAF plus MEK inhibitors vs BRAF inhibitors
Overall survival† · people with cutaneous melanoma
BRAF plus MEK inhibitors leads to lower overall survival† compared with BRAF inhibitors (high certainty).
1 finding from 1 review
- HR 0.7 [0.59, 0.82]1784 participantsHigh
BRAF plus MEK inhibitors vs BRAF inhibitors
Progression‐free survival · people with cutaneous melanoma
BRAF plus MEK inhibitors probably leads to lower progression‐free survival† compared with BRAF inhibitors (moderate certainty).
1 finding from 1 review
- HR 0.56 [0.44, 0.71]1784 participantsModerate
BRAF plus MEK inhibitors vs BRAF inhibitors
Tumour response · people with cutaneous melanoma
BRAF plus MEK inhibitors leads to higher tumour response compared with BRAF inhibitors (high certainty).
1 finding from 1 review
- RR 1.32 [1.2, 1.46]1784 participantsHigh
BRAF plus MEK inhibitors vs BRAF inhibitors
Toxicity (≥ G3) · people with cutaneous melanoma
BRAF plus MEK inhibitors showed no clear difference in toxicity (≥ G3) compared with BRAF inhibitors (moderate certainty).
1 finding from 1 review
- RR 1.01 [0.85, 1.2]1774 participantsModerate